News
Vinay Prasad is back at the FDA after last month's surprise ouster. Will he stay this time?
Vinay Prasad, M.D., has rejoined the FDA, the latest turn in a monthslong stretch of leadership turnover at the agency. | “At the FDA’s request, Dr. Vinay Prasad is resuming leadership of the Center for Biologics Evaluation and Research,
Less than weeks after stepping down, Prasad will return to lead CBER “at the FDA’s request,” according to an HHS spokesperson ...
But this time, the unknown is hitting the industry in a different way from when Prasad was tapped to lead CBER less than three months ago.
Precigen's immunotherapy for a rare respiratory disease has become the first treatment to win U.S. regulatory approval for ...
The FDA approved the adenoviral vector-based immunotherapy, zopapogene imadenovec-drba, for treatment of certain patients ...
DermaRite Industries is recalling certain lots of its over-the-counter soaps, antiseptics, and analgesics due to ...
Prasad Returns, Delany Departs, Lilly’s Weight Loss Pill Disappoints and Sarepta’s Fallout Continues
CBER Chief Vinay Prasad reclaimed his job less than two weeks after his mysterious exit; MAHA implementor Gray Delany is out ...
Today, we discuss lots of government maneuvering that impacts biopharma — starting, of course, with the FDA reinstating Vinay ...
Vinay Prasad is once again head of the FDA’s Center for Biologics Evaluation and Research, after Laura Loomer led a campaign ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback